Correlation Between Eyepoint Pharmaceuticals and Protalix Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Eyepoint Pharmaceuticals and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eyepoint Pharmaceuticals and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eyepoint Pharmaceuticals and Protalix Biotherapeutics, you can compare the effects of market volatilities on Eyepoint Pharmaceuticals and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eyepoint Pharmaceuticals with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eyepoint Pharmaceuticals and Protalix Biotherapeutics.

Diversification Opportunities for Eyepoint Pharmaceuticals and Protalix Biotherapeutics

-0.12

Correlation Coefficient

Eyepoint Pharmaceuticals  Protalix Biotherapeutics

Good diversification

The 3 months correlation between Eyepoint and Protalix is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding Eyepoint Pharmaceuticals and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Eyepoint Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eyepoint Pharmaceuticals are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Eyepoint Pharmaceuticals i.e., Eyepoint Pharmaceuticals and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Eyepoint Pharmaceuticals and Protalix Biotherapeutics

Given the investment horizon of 90 days Eyepoint Pharmaceuticals is expected to generate 12.08 times less return on investment than Protalix Biotherapeutics. In addition to that, Eyepoint Pharmaceuticals is 1.33 times more volatile than Protalix Biotherapeutics. It trades about 0.01 of its total potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.22 per unit of volatility. If you would invest  106.00  in Protalix Biotherapeutics on September 12, 2024 and sell it today you would earn a total of  77.00  from holding Protalix Biotherapeutics or generate 72.64% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Eyepoint Pharmaceuticals  vs.  Protalix Biotherapeutics

Eyepoint Pharmaceuticals

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Eyepoint Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Eyepoint Pharmaceuticals is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Protalix Biotherapeutics

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Eyepoint Pharmaceuticals and Protalix Biotherapeutics

The main advantage of trading using opposite Eyepoint Pharmaceuticals and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eyepoint Pharmaceuticals position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.

The idea behind Eyepoint Pharmaceuticals and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.